For an elderly resident with dementia who is currently receiving high‑dose olanzapine and risperidone and becomes acutely agitated on a memory‑care unit, what is the most appropriate PRN medication to have available?

Oral Quetiapine is the Safest PRN Option for Acute Agitation in Memory Care

For an elderly resident with dementia experiencing acute behavioral escalation on a memory care unit, oral quetiapine (starting 25-50 mg, maximum 200 mg/day) should be the first-line PRN medication available, as it demonstrates the lowest adverse event profile among antipsychotics in this population. 1

Critical Context: This Patient is Already Over-Medicated

Before discussing PRN options, recognize that this resident is already receiving high-dose olanzapine AND risperidone concurrently—a dangerous polypharmacy situation that violates standard practice guidelines 2. This combination:

• Increases fall risk, sedation, and metabolic complications
• Provides no additional benefit over monotherapy
• Should be tapered and consolidated before adding any PRN agent

The Evidence-Based PRN Hierarchy

First-Line: Oral Quetiapine

The 2025 JAGS systematic review analyzing 838 older adults with severe agitation found quetiapine had the only statistically significant reduction in adverse events compared to haloperidol (OR 0.27,95% CI: 0.08-0.97) 1. This represents a 73% risk reduction—the strongest safety signal in the geriatric agitation literature.

Dosing strategy:

• Start: 25-50 mg PO
• May repeat once after 2 hours if needed
• Maximum: 200 mg/day total
• Available as tablets or liquid formulation

Second-Line: Ziprasidone (if oral route fails)

If the patient refuses oral medication and parenteral administration becomes necessary, ziprasidone showed zero adverse events (0/17 patients) in the JAGS review 1. However, parenteral administration should be minimized as it increases adverse event risk across all agents.

Avoid Completely: Benzodiazepines

Midazolam is contraindicated in older adults with dementia, showing a 53% adverse event rate and 5-fold increased risk (OR 5.25) compared to haloperidol 1. Even lorazepam, while less dangerous than midazolam, showed concerningly high adverse event rates at higher doses and with parenteral administration 1.

The only exception: documented alcohol or benzodiazepine withdrawal, where benzodiazepines become medically necessary 1.

The Non-Negotiable First Steps (Before Any PRN)

Per APA guidelines, antipsychotic PRN should only be used when symptoms are severe, dangerous, and/or cause significant distress 2. Before administering:

1. Assess for reversible causes (Statement 2) 2:

   • Pain (most common trigger)
   • Urinary retention or constipation
   • Infection (UTI, pneumonia)
   • Medication side effects from current olanzapine/risperidone
   • Environmental overstimulation

2. Attempt nonpharmacologic interventions first (Statement 6) 2:

   • Sensory reduction (quiet room, dim lights)
   • Person-centered communication
   • Caregiver engagement
   • Reorientation techniques

   These should be "exhausted prior to medication use" 1.

3. Offer oral formulation before considering parenteral 1—liquid quetiapine if tablet refusal occurs.

Critical Safety Monitoring

If PRN administration becomes necessary:

• Assess response at 2 weeks: If no improvement by week 2, the patient is unlikely to respond at week 8 3
• Quantify response: Use a validated measure like CMAI or NPI-NH 2
• Taper within 3-6 months: Determine lowest effective maintenance dose or discontinue entirely 2, 4
• Monitor for: Falls, sedation, orthostatic hypotension, QTc prolongation, extrapyramidal symptoms

The Underlying Problem: Baseline Antipsychotic Polypharmacy

This patient's current regimen requires urgent review. The combination of high-dose olanzapine plus risperidone:

• Violates APA recommendations for monotherapy at the "minimum effective dose" 2
• Increases cumulative adverse event burden
• Suggests inadequate assessment of treatment response (Statement 10: if no response after 4 weeks at adequate dose, taper and withdraw) 2

Action required:

1. Consolidate to single antipsychotic at lowest effective dose
2. Reassess whether continued antipsychotic is even indicated
3. Only then consider PRN availability

Common Pitfalls to Avoid

• Do not use standing olanzapine plus PRN olanzapine: Excessive cumulative dosing
• Do not combine antipsychotic with benzodiazepine PRN: No added benefit, excessive risk 1
• Do not use PRN as substitute for addressing underlying causes: Behaviors are symptoms requiring root cause treatment 5
• Do not continue PRN indefinitely: 42% of behavioral symptoms resolve spontaneously within 6 months 5

Practical Implementation

Stock on unit: Quetiapine 25 mg and 50 mg tablets (or liquid formulation)

PRN order parameters:

• Indication: Severe agitation unresponsive to nonpharmacologic interventions
• Dose: 25-50 mg PO once, may repeat x1 after 2 hours
• Maximum: 200 mg/24 hours
• Hold parameters: Sedation, hypotension (SBP <90), falls
• Mandatory documentation: Trigger behavior, interventions attempted before medication, response within 2 hours

2, 1, 6, 4